Clinical trialsCompany release
CervoMed presents interim 24-week NfL data for neflamapimod in nfvPPA at CTAD
🇺🇸 CervoMed Inc. (CRVO) · Mon 16 Nov 2026
Plasma neurofilament light chain stayed stable overall and fell at the highest drug exposures in the 19-patient US cohort of a Phase 2a trial, with no new safety signals.
CervoMed presented interim 24-week biomarker results on 16 November 2026 at the CTAD conference from its Phase 2a trial of oral neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): CervoMed Inc. ↗
Article written by VigiEye from the official source (CervoMed Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3
🇺🇸 Kyntra Bio, Inc. (KYNB) · Mon 16 Nov 2026
Connect Biopharma reports Q3 loss, plans FDA Phase 3 talks for rademikibart
🇺🇸 Connect Biopharma Holdings Ltd (CNTB) · Mon 16 Nov 2026
ORIC starts Phase 3 Himalayas-1 of rinzimetostat with Bayer's darolutamide in mCRPC
🇺🇸 Oric Pharmaceuticals, Inc. (ORIC) · Mon 16 Nov 2026
Enanta reports $68.2m annual loss as RSV drug zelicapavir moves through Phase 2b trials
🇺🇸 Enanta Pharmaceuticals Inc (ENTA) · Mon 16 Nov 2026
Acrivon adds oral JAK1 inhibitor ACR-525 as ACR-368 interim analysis nears
🇺🇸 Acrivon Therapeutics, Inc. (ACRV) · Mon 16 Nov 2026
Traws Pharma reports Phase 2a ratutrelvir data and plans Q4 resubmission for flu drug
🇺🇸 Traws Pharma, Inc. (TRAW) · Mon 16 Nov 2026